Broadfin Capital Llc Upped Horizon Pharma Plc (NASDAQ:HZNP) Position as Price Declined by $31.70 Million

May 17, 2018 - By Catherine Smith

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Corporate LogoDuring Q4 2017 the big money sentiment increased to 1.04. That’s change of 0.04, from 2017Q3’s 1. 30 investors sold all, 53 reduced holdings as HZNP ratio increased. 53 increased holdings while 33 funds took holdings. Funds hold 128.65 million shares thus 2.76% less from 2017Q3’s 132.29 million shares. Ubs Asset Mngmt Americas has 104,024 shs. Citadel Advsr Limited Liability Co reported 654,433 shs. Federated Invsts Pa holds 0.01% or 265,760 shs. Alps Advisors invested in 181,604 shs. Hudson Bay Cap Management Ltd Partnership accumulated 50,000 shs or 0.02% of the stock. Knott David M has 25,000 shs for 0.15% of their capital. Moreover, Eaton Vance Management has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 27,000 shs. Stratos Wealth Limited owns 8,050 shs. Blackrock invested in 0.01% or 13.45M shs. Creative Planning has invested 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Morgan Stanley holds 495,371 shs or 0% of its capital. Contravisory Invest Mngmt Inc accumulated 0% or 43 shs. 4.04M were reported by State Street Corporation. Millennium Management Limited holds 281,651 shs or 0.01% of its capital. Parallax Volatility Advisers Lp holds 0% or 24,822 shs.

In 2018Q1 Securities and Exchange regulatory filling was reported Broadfin Capital Llc’s stake in Horizon Pharma Plc (NASDAQ:HZNP) which was increased by 754.73%. 2.26M shares were bought by Broadfin Capital Llc as Horizon Pharma Plc (NASDAQ:HZNP) stock declined 6.58% with the market. In 2018Q1, Broadfin Capital Llc held 2.56M shares of Horizon Pharma Plc (NASDAQ:HZNP), priced at $36.41M, up from 300,000 last quarter. $2.47 billion is the market cap of Horizon Pharma Plc. HZNP touched $14.97 during the last trading session after $0.09 change.Horizon Pharma Public Limited Company has volume of 1.01 million shares. Since May 17, 2017 HZNP has declined 6.20% and is downtrending. The stock underperformed the S&P500 by 17.75%.

It decreased Iovance Biotherapeutics Inc () position by 1.43 million shares to 912,987 shares, and cut its Angiodynamics Inc (NASDAQ:ANGO) stake.

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Total analysts of 6 have positions in Horizon Pharma Inc (NASDAQ:HZNP) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. Since November 30, 2017 according to StockzIntelligence Inc Horizon Pharma Inc has 11 analyst reports. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Sunday, April 15. In Wednesday, February 28 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Wednesday, February 28 Cowen & Co maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) with “Buy” rating. In Wednesday, February 28 report Piper Jaffray maintained it with “Buy” rating and $22.0 target. On Friday, March 2 the firm earned “Equal-Weight” rating by Morgan Stanley. On Friday, January 12 the stock has “Buy” rating by Mizuho. On Monday, May 7 the firm has “Buy” rating given by Mizuho. On Thursday, November 30 UBS maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) with “Buy” rating. The company rating was maintained by Mizuho on Wednesday, April 11. On Tuesday, January 30 the firm earned “Buy” rating by Piper Jaffray.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally.The company has $2.47 billion market cap. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout.Last it reported negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: